Articles tagged "IVIG"

2016 American Transplant Congress
Clinical and Immunologic Assessments of Immune Responses in a Liver Transplant Patient with CD40L Deficiency and Hyper IgM Syndrome.
M. Tseng,¹ S. Ge,¹ R. Roberts,² C. Kuo,² J. Choi,¹ N. Nissen,¹ M. Chu,¹ I. Kim,¹ B. Shin,¹ M. Toyoda,¹ S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Pediatrics & Immunology, UCLA, Los Angeles, CA.
Introduction: Monoclonal antibodies that disrupt CD40/CD40 ligand (CD40L) interactions are likely to have utility in human transplantation. However, the extent of the immunosuppressive effects of…
2016 American Transplant Congress
The Preventive and Therapeutic Effect of Immunoglobulin on Infectious Complications in Donation After Cardiac Death Liver Transplant Recipients: A Prospective Randomized Controlled Study.
A. Yang, Z. Guo, W. Ju, Y. Chen, M. Han, X. Wang, D. Wang, Y. Ma, A. Hu, X. Zhu, X. He.
Organ Transplantation Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Aims: To prospectively investigate the preventive and therapeutic effect of immunoglobulin on infectious complications in DCD liver transplant recipients, and synthetically evaluate its influence on…
2016 American Transplant Congress
Limited Hepatitis B Immune Globulin Following Liver Transplant for Hepatitis B.
T. Sievers, J. Thompson, J. Lake.
Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, MN.
IntroductionThe hypothesis of this study was that the long-term outcomes in liver transplant (LTx) patients with hepatitis B virus (HBV) who were treated with nucleos(t)ide…
2016 American Transplant Congress
Long-Term Assessment of the Safety and Efficacy of IVIG and Rituximab-Based Desensitization (DES).
J. Choi, J. Kahwaji, A. Vo, S. Louie, A. Kang, A. Peng, R. Villicana, D. Puliyanda, I. Kim, S. Jordan.
Comprehensive Transplantation Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: HLA sensitized patients constitute a growing number of ESRD patients with an immunologic barrier to successful transplantation. Desensitization (DES) therapies have emerged to address…
2016 American Transplant Congress
Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
A. Vo,¹ X. Zhang,² S. Williamson,¹ K. Myers,¹ N. Reinsmoen,² J. Choi,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²HLA Laboratory, Cedars-Sinai Medical Center, LA, CA.
Introduction: HS patients not desensitized (DES) receiving transplants are at risk for ABMR. DES improves transplant rates, but is limited to donor availability. Implementation of…
2016 American Transplant Congress
Incidence & Impact of De Novo DSA (dnDSA) Formation on Transplant Outcomes in HLA-Sensitized (HS) Patients Transplanted After IVG+Rituximab Desensitization (DES).
A. Vo,¹ J. Choi,¹ J. Kahwaji,¹ J. Mirocha,² A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²Research Institute, Cedars-Sinai Medical Center, LA, CA.
Introduction: Highly-HLA sensitized patients are at risk for developing donor specific antibodies (DSA) & ABMR post-transplant (tx). However, incidence and risk of acute rejections (AR)…
2015 American Transplant Congress
Extended Analysis of Tocilizumab (anti-IL-6R) + Intravenous Immunoglobulin (IVIG) as Desensitization (DES) Agents for Reduction of Donor Specific Antibodies (DSA) in Patients Resistant to DES With IVIG + Rituximab
A. Vo, J. Choi, I. Kim, J. Kahwaji, A. Peng, R. Villicana, S. Jordan.
Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: IVIG+rituximab is an acceptable approach for DES with good outcomes. Despite this, ∼30% of patients fail DES, thus other approaches are needed. Options include…
2015 American Transplant Congress
Long-Term Analysis of a Placebo-Controlled Trial of C1-INH for Prevention of Antibody-Mediated Rejection
A. Vo, J. Choi, J. Kahwaji, D. Puliyanda, A. Peng, R. Villicana, S. Jordan.
Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced antibody-mediated rejection (ABMR) and rebound B-cell activity. Recently,…
2015 American Transplant Congress
De Novo Donor Specific Antibody (DSA) After Treatment of BK Infection With Intravenous Immunoglobulin (IVIG)
J. Kahwaji, P. Wongsaroj, J. Choi, A. Peng, R. Villicana, S. Jordan, A. Vo.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: The primary treatment for polyomavirus BK viral infection (BKV) is a reduction in immunosuppression exposure. However this can lead to rejection and development of…
2015 American Transplant Congress
Should Current IVIg Preparations Containing High Titers of Anti-HLA-I/-II IgG be Used for Lowering the Anti-HLA IgG in Sensitized Pre-Transplant Patients and Allograft Recipients?
M. Ravindranath, P. Terasaki, C. Maehara, V. Jucaud.
HLA antibodies, Terasaki Foundation Laboratory, Los Angeles, CA.
Sera of non-alloimmunized individuals contain anti-HLA-I & -II IgG. Therefore it is reasonable expect HLA-I/-II reactivity of Intravenous Immunoglobulin (IVIg). However, the titers at which…